Cullinan Therapeutics Inc
CGEM
Market Cap$1.37B
Close$
$2.28
90.1% downside
Current Fair Value
90.1% downsideOvervalued by 90.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.37 Billion |
|---|---|
| Enterprise Value | - |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $0.0 |
| Beta | 1.8 |
| Outstanding Shares | 57,634,234 |
| Avg 30 Day Volume | 1,249,388 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 0.0 |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
Revenue Sources
No data
ESG Score
No data
About Cullinan Oncology Inc
24 employeesCullinan Management is a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients. The Company’s strategy is to build a pi...